Sorbent Therapeutics Inc. has raised a $21 million Series B round to fund Phase 2 clinical trials of a non-absorbed polymer-based drug for end-stage renal disease. The company’s renal disease drug, ...
Completes Enrollment in Phase 2b Clinical Trial of CLP-1001 for Heart Failure SUNNYVALE, Calif., May 15, 2014 / -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for ...
Sunnyvale, California - September 10, 2010 - Sorbent Therapeutics, a biopharmaceutical company developing therapies for patients requiring sodium, potassium and fluid removal, announced today that it ...
Aussies have been warned they're going to have to add another Christmas price hike to their end-of-year bill after one of the nation's biggest toilet paper producers admitted its skyrocketing gas bill ...
Sorbent partnered with The Edison Agency to develop its brand identity strategy, design system and portfolio architecture strategy to rejuvenate its portfolio across all products lines. The Sorbent ...
Dotz Nano Limited (“Dotz”), a leading developer of innovative climate and industrial nanotechnologies, has signed a Memorandum of Understanding (MOU) with direct air capture (DAC) leader, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results